Supplementary Tables and Supplementary Figure Legend from A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

Supplementary Table S1. Adverse events that led to dose interruption or reduction Supplementary Table S2. Treatment-related Psychiatric Adverse Events (AEs) Supplementary Table S4. PgR Status of the Primary versus Metastatic (Recurrent) Disease of the 29 Evaluable Patients